Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 versus blinatumomab in relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia
jRCT2031260140Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing MK-1045 arm with Blinatumomab arm (2 arms). Primary endpoints: Complete remission within the first 3 treatment cycles (Part 1), Adverse events (Part 1) and 3 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CN201blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031260140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260140.